Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | INMT | O95050 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339880 | 0.94 | L3MBTL1 (0.42) | L3MBTL1MEN1PKMKMT2AINMT | |
| SCHEMBL2347716 | 0.82 | L3MBTL1 (0.39) | L3MBTL1MEN1PKMKMT2AINMT | |
| SCHEMBL13377947 | 0.81 | ALDH1A1 (0.43) | L3MBTL1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1760423 | 0.78 | ALDH1A1 (0.41) | L3MBTL1MEN1PKMKMT2AINMT | |
| SCHEMBL898825 | 0.76 | POLB (0.47) | L3MBTL1MEN1PKMKMT2AALDH1A1 | |
| SCHEMBL874422 | 0.76 | HRH1 (0.41) | ALDH1A1KDM4ETSHRHSD17B10CYP2C9 | |
| SCHEMBL13378024 | 0.74 | KDM4E (0.47) | ALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL9947197 | 0.73 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9903440 | 0.72 | L3MBTL1 (0.38) | L3MBTL1MEN1PKMKMT2AINMT | |
| SCHEMBL2344594 | 0.71 | POLB (0.46) | L3MBTL1MEN1PKMKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695445-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2020-06-30 | — | — | US | claimed |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-01-24 | — | — | US | claimed |
| US-20160045619-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT INC. | 2016-02-18 | — | — | US | claimed |
| EP-1986701-B1 | OPTICAL AGENTS FOR USE IN SURGERY | MALLINCKRODT LLC (US) | 2012-06-13 | — | — | EP | claimed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | claimed |
| EP-1986701-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT, INC. (US) | 2008-11-05 | — | — | EP | claimed |
| WO-2007106142-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20240125703-A1 | SYSTEMS AND METHODS FOR QUANTIFYING USER OBSERVED VISUALIZATION OF FLUORESCENCE IMAGING AGENTS | STRYKER CORPORATION | 2024-04-18 | — | — | US | disclosed |
| WO-2024059825-A1 | SYSTEMS AND METHODS FOR QUANTIFYING USER OBSERVED VISUALIZATION OF FLUORESCENCE IMAGING AGENTS | STRYKER CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023088134-A1 | NOVEL BORONSOME FACILITATING DIAGNOSIS AND TREATMENT | 北京大学 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023069892-A1 | CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES | SHORT JAY M (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11351274-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-1986701-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT, INC. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1836175-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT, INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007106142-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106142-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006071759-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045619-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | L3MBTL1 4515/4885MEN1 327/4885PKM 3005/4885 |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | HMGB1, PAICS, CCL2 | L3MBTL1 2655/4885MEN1 1575/4885PKM 2079/4885 |
| US-10695445-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | L3MBTL1 4515/4885MEN1 327/4885PKM 3005/4885 |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | L3MBTL1 4515/4885MEN1 327/4885PKM 3005/4885 |
| US-11351274-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | L3MBTL1 4515/4885MEN1 327/4885PKM 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.